236 related articles for article (PubMed ID: 16243370)
1. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.
Tovar Sepulveda VA; Falzon M
Mol Cell Endocrinol; 2003 Jun; 204(1-2):51-64. PubMed ID: 12850281
[TBL] [Abstract][Full Text] [Related]
3. Regulation of renal parathyroid hormone receptor expression by 1, 25-dihydroxyvitamin D3 and retinoic acid.
Sneddon WB; Barry EL; Coutermarsh BA; Gesek FA; Liu F; Friedman PA
Cell Physiol Biochem; 1998; 8(5):261-77. PubMed ID: 9792954
[TBL] [Abstract][Full Text] [Related]
4. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
5. Retinoid X receptors stimulate and 9-cis retinoic acid inhibits 1,25-dihydroxyvitamin D3-activated expression of the rat osteocalcin gene.
MacDonald PN; Dowd DR; Nakajima S; Galligan MA; Reeder MC; Haussler CA; Ozato K; Haussler MR
Mol Cell Biol; 1993 Sep; 13(9):5907-17. PubMed ID: 8395017
[TBL] [Abstract][Full Text] [Related]
6. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
7. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
9. 9-cis retinoic acid accelerates calcitriol-induced osteocalcin production and promotes degradation of both vitamin D receptor and retinoid X receptor in human osteoblastic cells.
Jääskeläinen T; Ryhänen S; Mäenpää PH
J Cell Biochem; 2003 Aug; 89(6):1164-76. PubMed ID: 12898515
[TBL] [Abstract][Full Text] [Related]
10. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
11. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.
Kane KF; Langman MJ; Williams GR
Cancer Res; 1996 Feb; 56(3):623-32. PubMed ID: 8564982
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid on parathyroid hormone-related protein expression by oral cancer cells (HSC-3).
Abe M; Akeno N; Ohida S; Horiuchi N
J Endocrinol; 1998 Feb; 156(2):349-57. PubMed ID: 9518882
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors.
Pathrose P; Barmina O; Chang CY; McDonnell DP; Shevde NK; Pike JW
J Bone Miner Res; 2002 Dec; 17(12):2196-205. PubMed ID: 12469913
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors.
Fernandez-Martin JL; Kurian S; Farmer P; Nanes MS
Mol Cell Endocrinol; 1998 Jun; 141(1-2):65-72. PubMed ID: 9723887
[TBL] [Abstract][Full Text] [Related]
17. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression.
Sasaki H; Harada H; Handa Y; Morino H; Suzawa M; Shimpo E; Katsumata T; Masuhiro Y; Matsuda K; Ebihara K
Biochemistry; 1995 Jan; 34(1):370-7. PubMed ID: 7819220
[TBL] [Abstract][Full Text] [Related]
19. Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric receptor interactions.
Thompson PD; Jurutka PW; Haussler CA; Whitfield GK; Haussler MR
J Biol Chem; 1998 Apr; 273(14):8483-91. PubMed ID: 9525962
[TBL] [Abstract][Full Text] [Related]
20. 1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.
Bhatia V; Mula RV; Falzon M
Mol Cell Endocrinol; 2011 Aug; 342(1-2):32-40. PubMed ID: 21664243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
